StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$27.54−0.52 (-1.85%)

Close on Nov 19, 2026Market cap $156.97BP/E 36.2Yield 6.25%

Pfizer New Molecular Entities (NMEs) in pipeline by Quarter

Pfizer New Molecular Entities (NMEs) in pipeline: 56 in Q2 2026.

Latest, Q2 2026
56
Period ended Jun 28, 2026
Change on a year earlier
–
History
4 quarters
Since Q3 2025
Sources
4
Documents cited below

Where the Q2 2026 figure comes from

“▪ Included are 56 NMEs, 39 additional endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally indications advanced or metastatic breast cancer (MBC) following induction treatment. The approval is based on positive results from the Alliance Foundation Trials, LLC (AFT)- sponsored Phase 3 PATINA trial.”

Source: Pfizer Official Report — Q2 2026 Pipeline Update Final ↗

Reported in Form 8-K Earnings Release & Pfizer Quarterly Pipeline Update.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNew Molecular Entities (NMEs) in pipelineYear on yearSource
Q2 2026Jun 28, 202656–Pfizer Official Report — Q2 2026 Pipeline Update Final ↗
Q1 2026Mar 29, 202657–Pfizer Official Report — Q1 2026 Pipeline Update vFinal 0 ↗
Q4 2025Dec 31, 202561–Pfizer Official Report — Q4 2025 Pipeline Update vFinal3 ↗
Q3 2025Sep 28, 202559–Pfizer Official Report — Q3 2025 Pipeline Update vFinal2 ↗

Cite this data

StockData. (2026). Pfizer New Molecular Entities (NMEs) in pipeline, quarterly Q3 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/pipe-nmes

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?